Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer).
Main questions:
- What does the study drug do to human body (Pharmacodynamics [='PD'])
- What does the body do to study drug (how processed in body (Pharmacokinetics [='PK']) -
Safety
Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study
treatment continues as long as patient and their study doctor agree that study treatment is
in the best interest of the patient.